(RAY-B) RaySearch Laboratories - Ratings and Ratios

Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000135485

RAY-B: Treatment Planning, Oncology Information, Analytics, Control

RaySearch Laboratories AB (publ) (ST:RAY-B) is a pioneering medical technology company specializing in innovative software solutions for cancer care. With a global presence spanning the Americas, Europe, Africa, the Asia-Pacific, and the Middle East, RaySearch is committed to advancing radiation therapy through its integrated suite of products. The companys offerings include RayStation, a comprehensive treatment planning system; RayCare, an oncology information system that streamlines clinical workflows; RayIntelligence, a cloud-based analytics platform for enhancing cancer therapy outcomes; and RayCommand, a treatment control system that seamlessly connects treatment machines with planning and information systems. Additionally, RayPlan supports advanced radiation therapy planning, while µ-RayStation caters to small animal irradiation research.

Founded in 1988 and headquartered in Stockholm, Sweden, RaySearch has established itself as a leader in oncology software, dedicated to improving cancer treatment through cutting-edge technology. Their solutions are integral to modern radiation oncology, facilitating precise treatment planning and efficient clinical management.

3-Month Forecast: - Technical Outlook: - The stock is trading above its 20-day (225.40) and 50-day (241.13) moving averages, indicating short-term bullish momentum. However, its below the 200-day average (193.90), suggesting a longer-term downtrend. - Average True Range (ATR) of 12.68 signals moderate volatility, implying potential price swings. - Fundamental Outlook: - High P/E (39.23) and forward P/E (31.15) reflect strong growth expectations, driven by continued demand for advanced oncology solutions. - Elevated P/B (9.11) and P/S (6.70) ratios indicate investor confidence in future growth, supported by a robust return on equity (RoE) of 23.21%. - Projection: - Short-term gains are anticipated as the companys strong fundamentals and product pipeline align with market demand. However, investors should monitor volume trends and moving average crossovers to confirm the uptrends sustainability.

Additional Sources for RAY-B Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

RAY-B Stock Overview

Market Cap in USD 826m
Sector Healthcare
Industry Health Information Services
GiC Sub-Industry Health Care Technology
IPO / Inception

RAY-B Stock Ratings

Growth Rating 69.4
Fundamental 81.0
Dividend Rating 9.85
Rel. Strength 116
Analysts -
Fair Price Momentum 263.13 SEK
Fair Price DCF 72.29 SEK

RAY-B Dividends

Dividend Yield 12m 0.61%
Yield on Cost 5y 1.89%
Annual Growth 5y %
Payout Consistency 17.2%

RAY-B Growth Ratios

Growth Correlation 3m -47.7%
Growth Correlation 12m 92.5%
Growth Correlation 5y 46.2%
CAGR 5y 30.49%
CAGR/Max DD 5y 0.50
Sharpe Ratio 12m 0.54
Alpha 101.66
Beta 1.411
Volatility 38.71%
Current Volume 147.3k
Average Volume 20d 82k
What is the price of RAY-B stocks?
As of May 05, 2025, the stock is trading at SEK 262.00 with a total of 147,311 shares traded.
Over the past week, the price has changed by +5.65%, over one month by +23.88%, over three months by +3.97% and over the past year by +114.57%.
Is RaySearch Laboratories a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, RaySearch Laboratories (ST:RAY-B) is currently (May 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 81.02 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RAY-B as of May 2025 is 263.13. This means that RAY-B is currently overvalued and has a potential downside of 0.43%.
Is RAY-B a buy, sell or hold?
RaySearch Laboratories has no consensus analysts rating.
What are the forecast for RAY-B stock price target?
According to ValueRays Forecast Model, RAY-B RaySearch Laboratories will be worth about 315.8 in May 2026. The stock is currently trading at 262.00. This means that the stock has a potential upside of +20.52%.
Issuer Forecast Upside
Wallstreet Target Price 330 26%
Analysts Target Price - -
ValueRay Target Price 315.8 20.5%